Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm, Open-label, Phase II, Multicentre Study, to Assess the Safety of Vismodegib (GDC-0449) in Patient With Locally Advanced or Metastatic Basal Cell Carcinoma (BCC)

Next Previous
Trial Profile

A Single Arm, Open-label, Phase II, Multicentre Study, to Assess the Safety of Vismodegib (GDC-0449) in Patient With Locally Advanced or Metastatic Basal Cell Carcinoma (BCC)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Basal cell cancer
  • Focus Adverse reactions
  • Acronyms STEVIE
  • Sponsors Roche

    • Most Recent Events

    • 01 Feb 2023 Results of subgroup analysis of data from the STEVIE study establishing a model to predict treatment outcome of periocular locally advanced basal cell carcinoma based on initial response to treatment with vismodegib, published in the Eye
    • 12 Dec 2017 Results (n=6) of retrospective data from advanced BCC patients enrolled in this clinical trial who discontinued vismodegib due to PD and were then retreated with the same drug, were published in the Targeted Oncology.
    • 23 Oct 2017 Results of primary analysis (n=1215, data cut-off :16 Mar 2015), published in the European Journal of Cancer.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top